First-Line Treatment of Newly Diagnosed Multiple Myeloma With Bortezomib, Melphalan, and Prednisone (VMP Regimen)

A clinical practice guideline for patients with newly diagnosed symptomatic multiple myeloma. The guideline examines the use of bortezomib, melphalan, and prednisone (VMP regimen) as first-line treatment. Outcomes of interest include overall survival and time to progression.